about
Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data.Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical dataSimulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.Translational learning from clinical studies predicts drug pharmacokinetics across patient populations.Translational pharmacokinetics: challenges of an emerging approach to drug development in stroke.A comparison of approximation techniques for variance-based sensitivity analysis of biochemical reaction systems.Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic.Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.Using physiologically-based pharmacokinetic-guided "body-on-a-chip" systems to predict mammalian response to drug and chemical exposureAlternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.Biodistribution and Clearance of TiO2 Nanoparticles in Rats after Intravenous Injection.Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content.Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.Using modeling to help understand vaginal microbicide functionality and create better products.Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.Whole-body physiologically based pharmacokinetic models.Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.Development of translational pharmacokinetic-pharmacodynamic modelsPhysiologically based pharmacokinetics of matrine in the rat after oral administration of pure chemical and ACAPHAModeling kinetics of subcellular disposition of chemicals.A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancyModelling and PBPK simulation in drug discovery.Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.Physiologically based pharmacokinetics (PBPK).State of the art in therapeutic drug monitoring.Multiscale modeling in drug discovery and development: future opportunities and present challenges.The role of exposure reconstruction in occupational human health risk assessment: current methods and a recommended framework.A review of psychophysiological stressors on pharmacokinetics.Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?Preclinical in vivo ADME studies in drug development: a critical review.Understanding the particokinetics of engineered nanomaterials for safe and effective therapeutic applications.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Tools for predicting the PK/PD of therapeutic proteins.Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy.In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.Quantitative Evaluation and Prediction of Drug Effects and Toxicological Risk Using Mechanistic Multiscale Models.Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement.Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.
P2860
Q30585329-9563B2C5-3EEA-45E4-AEC5-2FAA9B2933FCQ30666721-5B9AD4F8-7D26-4D1D-9FFE-91FCEFDEDBEAQ33571451-F34FA3F8-AD14-40D7-A8EB-0DEB96E0A3CFQ33767468-B1293955-4FD8-4FA0-9553-55F2D7C061C1Q33882182-AA0CC1F2-2054-44AB-BB78-7B572A48F0E8Q33948743-DC373048-2D70-4738-AD0C-5C055B682604Q33997903-3220BC1E-4BA5-4120-94A7-D6E178DBB91BQ34099756-4CC1EDEB-15DA-4AB2-B4D5-EEB2FEA9A261Q34143269-9BBAE611-A542-4866-A9D5-8BB0D64DA472Q34181630-448E1201-D037-42FD-905E-232BAB134582Q35054518-123279E1-D115-4525-8A63-798B19F4CF3CQ35536445-6380C14E-1CC7-4210-B316-985276E81115Q35822288-3BA47D91-3194-45E0-AA31-DB1A34D0088FQ35827012-21F00C21-F2C9-411A-8613-453DA3FD8749Q35913838-728BD546-C951-4C62-988C-BDE7840C4C0AQ35999409-16CA28FC-0159-4300-A722-D83B0C6103BAQ36788418-58E61129-01C8-4AEB-9419-00E006A0559BQ36910606-357436B6-3126-49E5-9C7B-A3A435635B41Q37008900-A2702B8D-5952-4FFA-BB29-DA245E4F6D51Q37128660-D5073FD0-7F07-4B9E-B572-344B53948826Q37188046-D92C2583-F4BD-44EC-B11B-5857B988B50BQ37194304-19B248D8-4ECF-4CDA-AE6B-9BF1A1AA110AQ37207844-1117C01B-F75D-4317-89D4-DD5AF8324526Q37413064-1526245D-AF1B-4D72-BD88-C09857F39CFAQ37504548-E0831EC4-0D1C-48DB-8385-A5675C594107Q37550553-013A7C3D-99CB-4736-B80B-9389458E22C0Q37699413-7100142F-BFF3-4926-8721-C347E2BCE285Q37762442-99A9623F-C9E2-47D4-A250-1A0C6D74DF5EQ37781049-2FB9FC39-C675-4679-9FB9-34F080EBA74CQ37831732-805F1044-05A3-4868-B189-84454B422287Q37974113-9392D0E0-75D9-4510-8B38-3C2AAAF662BAQ37976124-4D1AD942-127A-4416-9F73-0926F7DC804CQ38066154-F4789AFC-54A8-45C5-AADF-E582E9E68E38Q38072598-491C4FFC-3680-475D-ABA1-E569E9487248Q38455786-059A5270-021D-4A9B-889D-36B3B1E080DAQ38765188-844BE1ED-C2BE-4FA6-989E-41AFB1B0AB33Q38765921-4FA775E3-D747-4311-A3CA-E1DB53F32A15Q38915439-FCD4973B-7D76-4940-B06C-5C9B403D64BDQ38926514-3FE8F7B7-D697-489B-A61A-097726347B39Q38959281-414EA5E8-3026-416F-9D00-B3332F42FDE6
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Whole body pharmacokinetic models.
@ast
Whole body pharmacokinetic models.
@en
type
label
Whole body pharmacokinetic models.
@ast
Whole body pharmacokinetic models.
@en
prefLabel
Whole body pharmacokinetic models.
@ast
Whole body pharmacokinetic models.
@en
P1476
Whole body pharmacokinetic models.
@en
P2093
Ivan Nestorov
P304
P356
10.2165/00003088-200342100-00002
P577
2003-01-01T00:00:00Z
P5875
P6179
1021758339